Becton, Dickinson and Co (BDX) said Wednesday it is launching its Phasix ST umbilical hernia patch after receiving 510(k) clearance from the US Food and Drug Administration.
The product is designed to duplicate the form, function and technique of the Ventralex ST hernia patch, which has more than 2 million implants globally, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.